1 / 52

Scleroderma

Scleroderma. Three major disease subsets: Based on extent of skin dz Diffuse disease - skin abnormalities extending to the proximal extremities (AKA - PSS) Limited disease AKA "CREST" syndrome Calcinosis, Raynauds, Esophageal dysmotility Sclerodactyly, Telangiectasias Localized Scleroderma

rocco
Download Presentation

Scleroderma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Scleroderma Three major disease subsets: Based on extent of skin dz • Diffuse disease - skin abnormalities extending to the proximal extremities (AKA - PSS) • Limited disease AKA "CREST" syndrome • Calcinosis, Raynauds, Esophageal dysmotility Sclerodactyly, Telangiectasias • Localized Scleroderma • Morphea: manifests as focal patches • Linear scleroderma: band-like (linear) areas of thickening. (Coup de Sabre)

  2. Other causes of Tight Skin • Pseudosclerodactyly • IDDM, Hypothyroidism • Drugs: Tryptophan, bleomycin, pentazocine, vinyl chloride, solvents • Eosinophilic fasciitis • Overlap Conditions • Scleroderma-like conditions • Eosinophil myalgia syndrome (tryptophan) • Porphyria cutanea tarda

  3. ACR Systemic Sclerosis Preliminary Classification Criteria* • Major Criterion • Proximal Scleroderma • Minor Criteria • Sclerodactyly • Digital pitting or scars or loss of finger pad • Bibasilar pulmonary fibrosis * One major and two minor required for diagnosis

  4. Scleroderma: Onset • 80% females • Age: 50% are < 40 yrs @ onset (20-50) • Incidence 20/million/year • Raynauds • Swollen or puffy digits • Loss of skin folds, no hair growth • Digital pulp sores/scars • Arthralgias >> Arthritis

  5. SclerodermaA disorder of Collagen, Vessels • Etiology: unknown? • Autoimmune disorder suggested by the presence of characteristic autoantibodies such as ANA, anti-centromere and anti-SCL-70 antibodies. • Pathology: • Early dermal changes lymphocytic infiltrates primarily of T cells • Major abnormality is collagen accumulation with fibrosis. • Small to medium-sized blood vessels, which show bland fibrotic change. • Small thrombi may form on the altered intimal surfaces. • Microvascular disease Cold Normal Cold PSS

  6. PSS - Clinical • Skin: • Skin thickening is most noticeable in the hands, looking swollen, puffy, waxy. • Thickening extends to proximal extremity, truncal and facial skin thickening is seen. • Raynaud's phenomenon is present. • Digital pits or scarring of the distal digital pulp • Musculoskeletal: Arthralgias and joint stiffness are common. • Palpable tendon friction rubs associated with an increased incidence of organ involvement. • Muscle weakness or frank myositis can be seen.

  7. PSS - Clinical • Gastrointestinal: Esophageal dysmotility, dysphagia, malabsorptive or blind loop syndrome, constipation. • Renal: Kidney involvement is an ominous finding and important cause of death in diffuse scleroderma. A hypertensive crisis (AKA renal crisis) may herald the onset of rapidly progressive renal failure.

  8. Pulmonary Manifestations of PSS • Dyspnea • Pulmonary HTN only in CREST • Interstitial fibrosis (fibrosing alveolitis) • High resolution CT vs Galium Scan • Major cause of death • RARE: • Pulmonary embolism • Pulmonary vasculitis

  9. Cardiac Findings in PSS • Myocardial fibrosis • Dilated cardiomyopathy • Cor pulmonale • Arrhythmias • Pericarditis • Myocarditis • Congestive heart failure

  10.  Feature Limited+ CREST Diffuse+ PSS  Calcinosis ++ +  Arthralgia/Arthritis  ++  ++++  Pulmonary fibrosis  +  ++  Pulmonary HTN  +  0  Tend friction rubs  0 +++  Renal crisis 0  +  Centromere Ab*  +++ +/0  Anti-Scl 70 Ab + ++ Comparison CREST v. PSS * Ab: antibody + Relative percentages: +++++ 81-100%; ++++ 61-80%; +++ 41-60%; ++ 21-40%; + 1-20%

  11. Treatment of Scleroderma • Localized: none • Raynauds: warmth, skin protection, vasodilator therapy • CREST: none • PSS: none proven • Penicillamine: controversy • Cytoxan: for lung disease? • Steroids have no value

  12. PolymyositisDermatomyositis • F:M = 2:1 • Acute onset • Weakness (+ myalgia): Proximal > Distal • Skeletal muscle: dysphagia, dysphonia • Sx: Rash, Raynauds, dyspnea • 65% elevated CPK, aldolase • 50% ANA (+) • 90% +EMG; 85% + muscle biopsy

  13. Proposed Criteria for Myositis • Symmetric proximal muscle weakness • Elevated Muscle Enzymes (CPK, aldolase, AST, ALT, LDH) • Myopathic EMG abnormalities • Typical changes on muscle biopsy • Typical rash of dermatomyositis • PM Dx is Definite w/ 4/5 criteria and Probable w/3/5 criteria • DM Dx Definite w/ rash and 3/4 criteria and Probable w/ rash and 2/4 criteria

  14. Polymyositis ClassificationBohan & Peter • Primary idiopathic dermatomyositis • Primary idiopathic polymyositis • Adult PM/DM associated with neoplasia • Childhood Dermatomyositis (or PM) • often associated with vasculitis • Myositis associated with collagen vascular disease

  15. MYOPATHY: HISTORICAL CONSIDERATIONS • Age/Sex/Race • Acute vs. Insidious Onset • Distribution: Proximal vs. Distal • Pain? • Drugs/Pre-existing Conditions • Neuropathy • Systemic Features

  16. MYOPATHIIES • Toxic/Drugs • Etoh, Cocaine, Steroids, Plaquenil, Penicilamine, Colchicine, AZT, Lovastatin, Clofibrate, Tryptophan, Taxol, Emetine • Infectious • Coxackie A9, HBV, HIV, Stept., Staph, Clostridial, Toxoplasma, Trichinella • Inflammatory Myopathies • Congenital • Neuropathic/Motor Neuron Disorders • Endocrine/Metabolic

  17. INFLAMMATORY MYOSITISImmunopathogenesis • Infiltrates - T cells (HLA-DR+) & monocytes • Muscle fibers express class I & II MHC Ags • T cells are cytotoxic to muscle fibers • t-RNA antibodies: role? FOUND IN <50% OF PTS • Infectious etiology? Viral implicated • HLA-B8/DR3 in childhood DM • DR3 and DRW52 with t-RNA synthetase Ab

  18. DERMATOMYOSITIS5 Skin Features • Heliotrope Rash: over eyelids • Seldom seen in adults • Gottrons Papules: MCPs, PIPs, MTPs, knees, elbows • V-Neck Rash: violaceous/erythema anterior chest w/ telangiectasias • Periungual erythema, digital ulcerations • Calcinosis

  19. Calcinosis

  20. DIAGNOSTIC TESTING • Physical Examiniation: Motor Strength (Gowers sign), Neurologic Exam • Acute phase reactants unreliable • Muscle Enzymes • CPK: elevated >65%; >10% MB fraction is possible • Muscle specific- Aldolase, Troponin, Carb. anhydraseIII • AST > LDH > ALT • Beware of incr. creatinine (ATN) and myoglobinuria • Electromyogram: increased insertional activity, amplitude, polyphasics, associated neuropathic changes, incremental/decremental MU changes

  21. DIAGNOSTIC TESTING • Muscle Biopsy (an URGENT not elective procedure) • Call the neuropathologist! 85% Sensitive. • Biopsy involved muscle (MRI guided) • Avoid EMG/injection sites or sites of trauma • Magnetic Resonance Imaging - detects incr. water signal, fibrous tissue, infiltration, calcification • Investigational: Tc-99m Scans, PET Scans • Serologic Tests: ANA (+) 60%, Abs against t-RNA synthetases

  22. INFLAMMATORY MYOSITISBiopsy Findings • Inflammatory cells • Edema and/or fibrosis • Atrophy/ necrosis/ degeneration • Centralization of nuclei • Variation in muscle fiber size • Rarely, calcification

  23. Anti-synthetase syndrome: ILD, fever, arthritis, Raynauds, Mechanics hands

  24. MALIGNANCY & MYOSITIS • Controversial • Reports range from 10-25% • If real, men over age 50 yrs at greatest risk • Common tumors: Breast, lung, ovary, stomach, uterus, colon • 60% the myositis appears 1st, 30% neoplasm 1st, and 10% contemporaneously • Avoid invasive, expensive searches for occult neoplasia

  25. PULMONARY Aspiration pneumonitis Infectious pneumonitis Drug induced pneumonitis Intercostal, diagphragm involvement Fibrosing alveolitis RARE: Pulmonary vasculitis Pulmonary neoplasia CARDIAC Elev. CPK-MB Mitral Valve prolapse AV conduction disturbances Cardiomyopathy Myocarditis PM/DM Complications

  26. PM/DM Diagnosis • Symmetric progressive proximal weakness • Elevated muscle enzymes (CPK, LFTs) • Muscle biopsy evidence of myositis • EMG: inflammatory myositis • Characteristic dermatologic findings

  27. INFLAMMATORY MYOSITISTreatment • Early Dx, physical therapy, respiratory Rx • Corticosteroids : 60-80 mg/day • 80% respond within 12 weeks • Steroid resistant • Methotrexate • Azathioprine • IVIG, Cyclosporin, Chlorambucil: unproven • No response to apheresis

  28. PROGNOSIS • Poor in pts. with delayed Dx, low CPK, early lung or cardiac findings, malignancy • Neoplasia in 10% of adults • PT for muscle atrophy, contractures, disability • Kids:50% remission, 35% chr active disease • Adult < 20 yrs. do better than >55 yrs. • Adults: Mortality rates betw. 28-47% @ 7 yrs. • Relapses & functional disability are common • Death: due to malignancy, sepsis, pulm. or cardiac failure, and complications of therapy

More Related